Other languages Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.07 ^USD	+2.48%		+2.99%	-45.95%

Apr. 04	Top Premarket Gainers	MT
Mar. 19	H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Premarket Gainers	Apr. 04
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	Mar. 19
US Futures Trend Lower in Tuesday's Premarket as Investors Await Start of 2-Day Fed Meeting	Mar. 19
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15
Acurx Pharmaceuticals, Inc. Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2B Clinical Trial in Cdi Patients	Jan. 29
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients	Jan. 17
Acurx Pharmaceuticals, Inc. Announces Positive Phase 2B Results Showing 100% of Patients Who Has Clinical Cure with Ibezapolstat Also Has Sustained Clinical Cure	Dec. 11
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Acurx Reports 96% Clinical Cure Rate in Phase 2 Trial of Ibezapolstat in C. Difficile Infection; Shares Fall	Nov. 02
Acurx Pharmaceuticals, Inc. Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. Difficile Infection	Nov. 02
Acurx Pharmaceuticals, Inc. Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection	23-10-02
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
Acurx Pharmaceuticals, Inc. Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference	23-04-19
Fmw Media's Business Tv Show New to the Street Signs Acurx Pharmaceuticals, Inc. to Additional Six-Month Media Contract with Iconic Billboard Ads and Commercial Support	23-03-23
Acurx Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-14
Acurx Pharmaceuticals, Inc. Provides Business Update on Ibezapolstat Phase 2 Clinical Trial	23-03-06
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12
Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI At the 16Th Biennial Congress of the Anaerobe Society of America	22-08-02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Other languages

Filters